Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 3

1(33.3%)

N/A

1(33.3%)

3Total

Phase 2(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06225050Not ApplicableNot Yet Recruiting

M-2018-334 in Hematological Malignancies

Role: collaborator

NCT07084454Phase 3Enrolling By Invitation

Geriatric Oncology Care in Brazil: Remote Geriatric Assessment-Driven Interventions With Supportive Care

Role: collaborator

NCT03777410Terminated

Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

Role: collaborator

NCT03976531Completed

Geriatric Core Dataset (G-CODE) for Clinical Research in Elderly Cancer Patients

Role: collaborator

NCT02059213Phase 2Completed

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Role: collaborator

All 5 trials loaded